{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-023484","form_type":"8-K","ticker":"ELAN","cik":"0001739104","company_name":"Elanco Animal Health Inc","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.361784+00:00","generated_at":"2026-06-19T07:09:17.157318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Elanco Q4 revenue $988M (-11% YoY), full year net loss $74M; guides FY2023 revenue $4.28-4.4B","bullets":["Q4 revenue $988M (-11% reported, -6% CER); Pet Health $423M (-14%), Farm Animal $552M (-9%).","Q4 reported net loss $54M ($0.11 loss per share); adjusted net income $95M, adjusted EPS $0.19.","Full year 2022 revenue $4,418M (-7% reported); reported net loss $74M; adjusted EBITDA $1,023M (23.2% margin).","FY2023 guidance: revenue $4,280-4,400M; adjusted EBITDA $920-1,000M; adjusted EPS $0.74-0.83.","Initiated JAK inhibitor submission to FDA; received FDA approval for Bexacat (feline diabetes); EPA approval for Advantage/K9 Advantix relaunch; Bovaer launch expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-023484","json":"https://secwatch.observer/filing/0001104659-23-023484.json","markdown":"https://secwatch.observer/filing/0001104659-23-023484.md","text":"https://secwatch.observer/filing/0001104659-23-023484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/0001104659-23-023484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/tm237362d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:09:17.157318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5660c6a97fcee0c0c93bd16529e935434d82f7ed","claim":"Elanco Animal Health Inc updated its the full year and fiscal quarter ended December 31, 2022 guidance (initiated).","evidence_excerpt":"Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 21, 2023, announcing the results of operations for the full year and fiscal quarter ended December 31, 2022 and guidance for the full year and first half of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739104/000110465923023484/0001104659-23-023484-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year and fiscal quarter ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}